|
Cel sci Corporation (NYSE: CVM) |
|
Cel sci Corporation
CVM's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Cel Sci's sales fell
in the first quarter of 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -2.05 %
Cel Sci net loss increased from $-7 millions, to $-7 millions in first quarter of 2024,
• More on CVM's Growth
|
|
Cel Sci realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 10.61 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.95.
• More on CVM's Valuation
|
|
|
|
|
Cel Sci realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 10.61 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.95.
Cel Sci Price to Book Ratio is at 1.29 higher than Industry Avg. of -87993.38, and higher than S&P 500 Avg. of 0.01
• More on CVM's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com